Tiny Jaarsma

Dr. Tiny Jaarsma

Department of Health, Medicine and Caring Sciences, Linköping Univeristy, Building Kåkenhus, Room 6631, Campus Norrköping, Sweden
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2012 in European Heart Journal
Verified
Journal Article
Open access
PDF file
TMTask Force Members
Task Force Members
JMJohn J V Mcmurray
John J V Mcmurray
SAStamatis Adamopoulos
Stamatis Adamopoulos
SAStefan D Anker
Stefan D Anker
AAAngelo Auricchio
Angelo Auricchio
DRDocument Reviewers
Document Reviewers
The originally published version of this paper was incorrect. In the table on page 1816, the Class of recommendation and Level of evidence for ‘The patient is pacemaker dependent as a result of AV nodal ablation’ should have read ‘IIa’ and ‘B’ respectively.

1 July 2013 in Journal Of Hypertension
Verified
Journal Article
Open access
GMGiuseppe Mancia
Giuseppe Mancia
RFRobert Fagard
Robert Fagard
KNKrzysztof Narkiewicz
Krzysztof Narkiewicz
JRJosep Redon
Josep Redon
AZAlberto Zanchetti
Alberto Zanchetti
FZFaiez Zannad
Faiez Zannad
Because of new evidence on several diagnostic and therapeutic aspects of hypertension, the present guidelines differ in many respects from the previous ones. Some of the most important differences are listed below: 1. Epidemiological data on hypertension and BP control in Europe. 2. Strengthening of the prognostic value of home blood pressure monitoring (HBPM) and of its role for diagnosis and management of hypertension, next to ambulatory blood pressure monitoring (ABPM). 3. Update of the prognostic significance of night-time BP, white-coat hypertension and masked hypertension. 4. Re-emphasis on integration of BP, cardiovascular (CV) risk factors, asymptomatic organ damage (OD) and clinical complications for total CV risk assessment. 5. Update of the prognostic significance of asymptomatic OD, including heart, blood vessels, kidney, eye and brain. 6. Reconsideration of the risk of overweight and target body mass index (BMI) in hypertension. 7. Hypertension in young people. 8. Initiation of antihypertensive treatment. More evidence-based criteria and no drug treatment of high normal BP. 9. Target BP for treatment. More evidence-based criteria and unified target systolic blood pressure (SBP) (<140 mmHg) in both higher and lower CV risk patients. 10. Liberal approach to initial monotherapy, without any all-ranking purpose. 11. Revised schema for priorital two-drug combinations. 12. New therapeutic algorithms for achieving target BP. 13. Extended section on therapeutic strategies in special conditions. 14. Revised recommendations on treatment of hypertension in the elderly. 15. Drug treatment of octogenarians. 16. Special attention to resistant hypertension and new treatment approaches. 17. Increased attention to OD-guided therapy. 18. New approaches to chronic management of hypertensive diseas

30 August 2024 in European Heart Journal
Verified
Journal Article
Closed access
IGIsabelle C Van Gelder
Isabelle C Van Gelder
MRMichiel Rienstra
Michiel Rienstra
KBKarina V Bunting
Karina V Bunting
RARuben Casado Arroyo
Ruben Casado Arroyo
VCValeria Caso
Valeria Caso
HKHusniddin Kuchkarov
Husniddin Kuchkarov

25 August 2023 in European Heart Journal
Verified
Journal Article
Closed access
TMTheresa A McDonagh
Theresa A McDonagh
MMMarco I. Metra
Marco I. Metra
MAMarianna Adamo
Marianna Adamo
RGRoy S Gardner
Roy S Gardner
ABAndreas Baumbach
Andreas Baumbach
IVIlonca Vaartjes
Ilonca Vaartjes

17 September 2008 in European Heart Journal
Verified
Journal Article
Open access
PDF file
KDK. Dickstein
K. Dickstein
ACAlain Cohen-Solal
Alain Cohen-Solal
GFG. Filippatos
G. Filippatos
JMJohn J.V. McMurray
John J.V. McMurray
PPPiotr Ponikowski
Piotr Ponikowski
FZFaiez Zannad
Faiez Zannad
Guidelines and Expert Consensus Documents summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians and other healthcare providers in selecting the best management strategies for a typical patient, suffering from a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines are no substitutes for textbooks. The legal implications of medical guidelines have been discussed previously.

1 August 2012 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
JMJohn J.V. McMurray
John J.V. McMurray
SAStamatis Adamopoulos
Stamatis Adamopoulos
SAStefan D. Anker
Stefan D. Anker
AAAngelo Auricchio
Angelo Auricchio
MBMichael Böhm
Michael Böhm
PPPiotr Ponikowski
Piotr Ponikowski